These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20198400)

  • 1. Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer.
    Ono A; Naito T; Murakami H; Takahashi T; Nakamura Y; Tsuya A; Kaira K; Igawa S; Shukuya T; Tamiya A; Kaira R; Endo M; Yamamoto N
    Int J Clin Oncol; 2010 Apr; 15(2):161-5. PubMed ID: 20198400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
    Chihara Y; Yoshimura A; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Takeuchi M; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
    Oncologist; 2019 Aug; 24(8):1033-e617. PubMed ID: 31040252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
    Tamiya A; Tamiya M; Shiroyama T; Saijo N; Nakatani T; Minomo S; Tsuji T; Takeuchi N; Omachi N; Kurata K; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
    Med Oncol; 2015 Mar; 32(3):40. PubMed ID: 25616723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
    Shiroyama T; Kijima T; Komuta K; Yamamoto S; Minami S; Ogata Y; Okafuji K; Imamura F; Hirashima T; Tachibana I; Kawase I; Kumanogoh A
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):783-9. PubMed ID: 22960985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated 
with More Than Two Lines of Chemotherapy].
    Yin Y; Wu B; Huang Z; Zhuang W; Xu Z; Huang C; Huang Y; Zhang J
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):437-444. PubMed ID: 29945701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
    Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
    J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
    Sugawara S; Nakagawa K; Yamamoto N; Nokihara H; Ohe Y; Nishio M; Takahashi T; Goto K; Maemondo M; Ichinose Y; Seto T; Sakai H; Gemma A; Imamura F; Shingyoji M; Saka H; Inoue A; Takeda K; Okamoto I; Kiura K; Morita S; Tamura T
    Int J Clin Oncol; 2019 May; 24(5):485-493. PubMed ID: 30830659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer.
    Goto H; Okano Y; Machida H; Hatakeyama N; Ogushi F; Haku T; Kanematsu T; Urata T; Kakiuchi S; Hanibuchi M; Sone S; Nishioka Y
    Respir Investig; 2018 Jan; 56(1):80-86. PubMed ID: 29325686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
    Ikemura S; Naoki K; Yasuda H; Kawada I; Yoda S; Terai H; Sato T; Ishioka K; Arai D; Ohgino K; Kamata H; Miyata J; Kabata H; Betsuyaku T; Soejima K
    Jpn J Clin Oncol; 2015 Apr; 45(4):356-61. PubMed ID: 25612761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer].
    Hashizume T; Nakada Y
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):963-7. PubMed ID: 19542716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Niho S; Ohe Y; Ohmatsu H; Umemura S; Matsumoto S; Yoh K; Goto K
    Lung Cancer; 2017 Jun; 108():66-71. PubMed ID: 28625650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
    Yumine K; Kawahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():189-92. PubMed ID: 16898000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.
    Shiroyama T; Komuta K; Imamura F; Hirashima T; Kijima T; Tachibana I; Kawase I
    Lung Cancer; 2011 Oct; 74(1):85-8. PubMed ID: 21342712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
    Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
    Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer.
    Miyoshi S; Ito R; Katayama H; Kadowaki T; Yano S; Watanabe A; Abe M; Hamada H; Okura T; Higaki J
    Int J Clin Oncol; 2014 Dec; 19(6):1005-10. PubMed ID: 24532162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation.
    Murakami S; Oshita F; Sugiura M; Kondo T; Saito H; Yamada K
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):705-11. PubMed ID: 23328865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
    Hata Y; Kiribayashi T; Kishi K; Nagashima M; Nakayama T; Ikeda S; Kadokura M; Ozeki Y; Otsuka H; Murakami Y; Takagi K; Iyoda A
    BMC Cancer; 2017 Aug; 17(1):581. PubMed ID: 28851314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
    Wada M; Yamamoto M; Ryuge S; Nagashima Y; Hayashi N; Maki S; Otani S; Katono K; Takakura A; Yanaihara T; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Masuda N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1005-11. PubMed ID: 22160350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.